aTYR PHARMA INC (ATYR): Shareholders' Equity
$67.48M
As of 2025-12-31
$48.79M
As of 2026-06-30
-1.9%
3-year compound annual growth
+16.3%
5-year compound annual growth
-5.2%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.48M | -3.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $70.02M | -22.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $90.66M | +26.9% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $71.46M | -34.6% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $109.30M | +245.3% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $31.65M | +49.4% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $21.19M | -37.0% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $33.65M | -47.6% | 2021-03-24, Balance as of period end |
| 2017-12-31 | $64.25M | +2.3% | 2020-03-26, Balance as of period end |
| 2016-12-31 | $62.80M | -45.4% | 2019-03-26, Balance as of period end |
| 2015-12-31 | $115.05M | n/m | 2018-03-20, Balance as of period end |
| 2014-12-31 | -$91.01M | n/m | 2017-03-16, Balance as of period end |
| 2013-12-31 | -$66.08M | n/a | 2016-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $67.48M | -3.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$514.9K | n/m |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$1.10M | n/m |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$9.78M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $23.52M | -26.7% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $133.14M | n/m |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $13.10M | +62.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | -$1.01B | n/m |
Compare ATYR, ZIVO, VIVS, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗